EL7.AI
StocksMediumUpdated•Originally published 23 March 2026•Updated 24 March 2026•
1 min read

Apogee Therapeutics Surges 14% on Potential Rival to Regeneron’s Blockbuster Eczema Drug

Key Facts

1Apogee Therapeutics shares rose 14% following positive reports regarding its potential eczema drug candidate.
2The new drug aims to compete with Regeneron's Dupixent, a dominant player in the eczema market.
3Analysts described the recent developments as a 'best case scenario' for Apogee.

Shares of Apogee Therapeutics surged 14% following the release of specific clinical data for its eczema treatment candidate, now identified as zumilokibart. The drug demonstrated impressive efficacy, achieving an EASI-75 response rate of 75-85% among responders by Week 16. A key competitive advantage is the extended dosing schedule, with intervals of every 3 or 6 months (Q3M and Q6M), positioning it as a strong rival to Regeneron’s Dupixent. The company has established a clear clinical roadmap, with Phase 2 data expected in Q2 2026 and the initiation of Phase 3 trials in the second half of 2026. Market analysts view these specific efficacy results and the long-term catalyst timeline as a "best-case scenario" for the firm's pipeline. This update reinforces investor confidence in Apogee’s potential to disrupt the dermatology market through superior dosing convenience and clinical performance.